Today, a Director at Resmed Inc (NYSE: RMD), Richard Sulpizio, bought shares of RMD for $783.4K.
This recent transaction increases Richard Sulpizio’s holding in the company by 382.79% to a total of $762.9K. Following Richard Sulpizio’s last RMD Buy transaction on August 11, 2017, the stock climbed by 31.4%.
See today’s analyst top recommended stocks >>
Based on Resmed Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $592 million and quarterly net profit of $110 million. In comparison, last year the company earned revenue of $514 million and had a net profit of $87.82 million. RMD’s market cap is $14.67B and the company has a P/E ratio of 48.04. Currently, Resmed Inc has an average volume of 205.7K.
Eight different firms, including Merrill Lynch and Citigroup, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $5.68M worth of RMD shares and purchased $783.4K worth of RMD shares. The insider sentiment on Resmed Inc has been negative according to 104 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Richard Sulpizio’s trades have generated a 4.7% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ResMed, Inc. engages in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders including sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.
